Drug Trial Radar · NCT03519945
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
Last checked: Nov 20, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,058
Actual
Start
Jul 18, 2018
Primary completion
Mar 4, 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Conditions
- Ulcerative Colitis
Interventions
MirikizumabDrug
Administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants in Clinical RemissionTime frame: Week 52
Locations
352 sites in 36 countries. Site status is shown where the registry gives one.
Digestive Health Specialists
Dothan, Alabama
Research Solutions of Arizona
Litchfield Park, Arizona
Valleywise Health Medical Center
Phoenix, Arizona
InSite Digestive Health Care
Arcadia, California
Care Access - Berkeley
Berkeley, California
Om Research LLC
Lancaster, California
California Medical Research Associates
Northridge, California
Inland Empire Clinical Trials, LLC
Rialto, California
Clinical Applications Laboratories, Inc.
San Diego, California
Direct Helpers Research Center
Hialeah, Florida
Encore Borland-Groover Clinical Research
Jacksonville, Florida
Wellness Clinical Research
Miami Lakes, Florida
AdventHealth Orlando
Orlando, Florida
Clintheory Healthcare
Orlando, Florida
Gastroenterology Associates of Pensacola, PA
Pensacola, Florida
Florida Medical Clinic LLC
Zephyrhills, Florida
Digestive Healthcare of Georgia
Atlanta, Georgia
Grand Teton Research Group
Idaho Falls, Idaho
NorthShore University HealthSystem - Evanston Hospital
Evanston, Illinois
Indiana University Health University Hospital
Indianapolis, Indiana
Cotton O'Neil Digestive Health Center
Topeka, Kansas
GI Alliance Research Baton Rouge
Baton Rouge, Louisiana
Delta Research Partners
Monroe, Louisiana
Nola Research Works, LLC
New Orleans, Louisiana
University of Michigan
Ann Arbor, Michigan
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan
Henry Ford Medical Center - Columbus Center
Novi, Michigan
West Michigan Clinical Research Center
Wyoming, Michigan
MNGI Digestive Health - Plymouth Endoscopy Center & Clinic
Plymouth, Minnesota
Columbia University Medical Center
New York, New York
Clinical & Translational Research Center (CTRC)
Chapel Hill, North Carolina
Carolina Digestive Diseases and Endoscopy Center
Greenville, North Carolina
Care Access - Youngstown
Poland, Ohio
The University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Central Sooner Research - Oklahoma - Northwest 47th Street
Oklahoma City, Oklahoma
Care Access - Pottsville
Pottsville, Pennsylvania
Digestive Disease Associates
Wyomissing, Pennsylvania
Midwest Medical Care
Sioux Falls, South Dakota
GI Alliance
Garland, Texas
Biopharma Informatic, LLC
Houston, Texas
Showing 40 of 352 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.